Jeyakumar A, Cabeza R, Hindenburg A
Oncology/Hematology Division, Winthrop University Hospital, Mineola, NY 11501, USA.
Gynecol Oncol. 2001 May;81(2):314-7. doi: 10.1006/gyno.2001.6135.
Ovarian dysgerminomas are quite amenable to treatment and very good cure rates are achieved even with advanced disease. However, recent literature suggests that late recurrence may be associated with a poorer prognosis and bleomycin/etoposide/cisplatin (BEP) chemotherapy may play only a limited role in its management. We present a patient who had a late recurrence of ovarian dysgerminoma with successful treatment outcome.
A 25-year-old woman was diagnosed with a stage IC ovarian dysgerminoma in 1983 and did not undergo adjuvant treatment. She had late recurrence 12 years later with good treatment response to BEP chemotherapy given in a semiadjuvant fashion.
Our case demonstrates that BEP chemotherapy still plays an important role in treatment of late recurrence in ovarian dysgerminomas provided there is small volume disease at time of detection. Also important is long-term surveillance in an effort to detect recurrence while still small in volume and potentially curable.
卵巢无性细胞瘤对治疗相当敏感，即使是晚期疾病也能取得很好的治愈率。然而，最近的文献表明，晚期复发可能与较差的预后相关，且博来霉素/依托泊苷/顺铂（BEP）化疗在其治疗中可能仅起有限作用。我们报告一例卵巢无性细胞瘤晚期复发且治疗成功的患者。
一名25岁女性于1983年被诊断为IC期卵巢无性细胞瘤，未接受辅助治疗。12年后出现晚期复发，以半辅助方式给予BEP化疗后治疗反应良好。
我们的病例表明，只要在检测时疾病体积较小，BEP化疗在卵巢无性细胞瘤晚期复发的治疗中仍起着重要作用。同样重要的是进行长期监测，以便在复发体积仍较小且可能治愈时就检测到复发。
